Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors

Department of Medicine, University of Auckland School of Medicine, New Zealand.

Activation of the adrenergic nervous system appears to play a crucial role in the genesis of fatal arrhythmias associated with the very early stages of acute myocardial infarction. The second messenger of beta-adrenergic catecholamine stimulation, cyclic adenosine monophosphate (AMP), has established arrhythmogenic qualities, acting by an increase in cytosolic calcium, which potentially has three adverse electrophysiologic effects. First, stimulation of the transient inward current by excess oscillations of cytosolic calcium can invoke delayed afterdepolarizations, so that triggered automaticity can develop in otherwise quiescent ventricular muscle. Second, cyclic AMP can evoke calcium-dependent slow responses in depolarized fibers, so that conditions for reentry are favored. Third, excess cytosolic calcium can cause intercellular uncoupling with conduction slowing. Focal changes in cyclic AMP and cytosolic calcium promote the development of ventricular fibrillation. Beta-adrenergic blockade can limit the formation of cyclic AMP in ischemic tissue. Furthermore, by reducing sinus tachycardia it can lessen cytosolic calcium overload. Hence, beta-adrenergic blockade helps to prevent ventricular fibrillation in the early stages of acute myocardial infarction and protects from sudden death in the postinfarction phase. In congestive heart failure, abnormalities of cytosolic calcium patterns exist with cytosolic calcium overload. It is proposed that the adverse effects of phosphodiesterase inhibitors on the mortality rate in patients with congestive heart failure can be explained by increased rates of formation of cyclic AMP and the development of calcium-dependent arrhythmias. Because calcium is the ultimate messenger of cyclic AMP-induced arrhythmias and because cytosolic calcium is increased in heart failure, it will be difficult to develop positive inotropic agents that are free of the risk of sudden death.

This article has been cited by other articles:

				G. W. Dorn II Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling Cardiovasc Res, February 15, 2009; 81(3): 465 - 473. [Abstract] [Full Text] [PDF]

				S. Grote-Wessels, H. A. Baba, P. Boknik, A. El-Armouche, L. Fabritz, H.-J. Gillmann, D. Kucerova, M. Matus, F. U. Muller, J. Neumann, et al. Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload Cardiovasc Res, August 1, 2008; 79(3): 464 - 471. [Abstract] [Full Text] [PDF]

				S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]

				K. Leineweber, M. Bohm, and G. Heusch Cyclic Adenosine Monophosphate in Acute Myocardial Infarction With Heart Failure: Slayer or Savior? Circulation, August 1, 2006; 114(5): 365 - 367. [Full Text] [PDF]

				D. Moertl, R. Berger, M. Huelsmann, A. Bojic, and R. Pacher Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure Eur J Heart Fail, December 1, 2005; 7(7): 1156 - 1163. [Abstract] [Full Text] [PDF]

				U. Kirchhefer, H. A. Baba, P. Boknik, K. M. Breeden, N. Mavila, N. Bruchert, I. Justus, M. Matus, W. Schmitz, A. A. DePaoli-Roach, et al. Enhanced cardiac function in mice overexpressing protein phosphatase Inhibitor-2 Cardiovasc Res, October 1, 2005; 68(1): 98 - 108. [Abstract] [Full Text] [PDF]

				A. E. Pollard, W. M. Smith, and R. C. Barr Feasibility of cardiac microimpedance measurement using multisite interstitial stimulation Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2402 - H2411. [Abstract] [Full Text] [PDF]

				J. J. Cai, D. A. Morgan, W. G. Haynes, J. B. Martins, and H.-C. Lee alpha 2-Adrenergic stimulation is protective against ischemia-reperfusion-induced ventricular arrhythmias in vivo Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2606 - H2611. [Abstract] [Full Text] [PDF]

				H.P Brunner-La Rocca, M.D Esler, G.L Jennings, and D.M Kaye Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure Eur. Heart J., July 1, 2001; 22(13): 1136 - 1143. [Abstract] [PDF]

				G. M. Janelle, F. Urdaneta, M. L. Blas, J. Shryock, Y.-S. Tang, T. D. Martin, and E. B. Lobato Inhibition of Phosphodiesterase Type III Before Aortic Cross-Clamping Preserves Intramyocardial Cyclic Adenosine Monophosphate During Cardiopulmonary Bypass Anesth. Analg., June 1, 2001; 92(6): 1377 - 1383. [Abstract] [Full Text] [PDF]

				D. O. Arnar, D. Xing, H.-C. Lee, and J. B. Martins Prevention of ischemic ventricular tachycardia of Purkinje origin: role for {alpha}2-adrenoceptors in Purkinje? Am J Physiol Heart Circ Physiol, March 1, 2001; 280(3): H1182 - H1190. [Abstract] [Full Text] [PDF]

				K. Nademanee, R. Taylor, W. E. Bailey, D. E. Rieders, and E. M. Kosar Treating Electrical Storm : Sympathetic Blockade Versus Advanced Cardiac Life Support-Guided Therapy Circulation, August 15, 2000; 102(7): 742 - 747. [Abstract] [Full Text] [PDF]

				W. T. Abraham {beta}-Blockers: The New Standard of Therapy for Mild Heart Failure Arch Intern Med, May 8, 2000; 160(9): 1237 - 1247. [Abstract] [Full Text] [PDF]

				R. M. Temsah, C. Dyck, T. Netticadan, D. Chapman, V. Elimban, and N. S. Dhalla Effect of beta -Adrenoceptor Blockers on Sarcoplasmic Reticular Function and Gene Expression in the Ischemic-Reperfused Heart J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 15 - 23. [Abstract] [Full Text]

				A. A. Shehadeh, J. Arena, C. B. Moschos, and T. J. Regan Nonplatelet Effects of Aspirin During Acute Coronary Occlusion: Electrophysiologic and Cation Alterations in Ischemic Myocardium Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(2): 113 - 120. [Abstract] [PDF]

				A. A. Grace and A.J. Camm Voltage-gated calcium-channels and antiarrhythmic drug action Cardiovasc Res, January 1, 2000; 45(1): 43 - 51. [Full Text] [PDF]

				E. F. Du Toit, C. A. Muller, J. McCarthy, and L. H. Opie Levosimendan: Effects of a Calcium Sensitizer on Function and Arrhythmias and Cyclic Nucleotide Levels during Ischemia/Reperfusion in the Langendorff-Perfused Guinea Pig Heart J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 505 - 514. [Abstract] [Full Text]

				C. A. Muller, L. H. Opie, J. McCarthy, D. Hofmann, C. A. Pineda, and M. Peisach Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise J. Am. Coll. Cardiol., July 1, 1998; 32(1): 268 - 274. [Abstract] [Full Text] [PDF]

				B. Felzen, M. Shilkrut, H. Less, I. Sarapov, G. Maor, R. Coleman, R. B. Robinson, G. Berke, and O. Binah Fas (CD95/Apo-1)–Mediated Damage to Ventricular Myocytes Induced by Cytotoxic T Lymphocytes From Perforin-Deficient Mice : A Major Role for Inositol 1,4,5-Trisphosphate Circ. Res., March 9, 1998; 82(4): 438 - 450. [Abstract] [Full Text] [PDF]

				R. Sandhu, U. Thomas, R. J. Diaz, and G. J. Wilson Effect of Ischemic Preconditioning of the Myocardium on cAMP Circ. Res., January 1, 1996; 78(1): 137 - 147. [Abstract] [Full Text]

				M. Epstein Calcium Antagonists Should Continue to Be Used for First-Line Treatment of Hypertension Arch Intern Med, November 13, 1995; 155(20): 2150 - 2156. [Abstract] [PDF]

				L. H. Opie and F. H. Messerli Nifedipine and Mortality : Grave Defects in the Dossier Circulation, September 1, 1995; 92(5): 1068 - 1073. [Full Text]

				G. W. Dec and V. Fuster Idiopathic Dilated Cardiomyopathy N. Engl. J. Med., December 8, 1994; 331(23): 1564 - 1575. [Full Text]